Xiangcai Yang
Xiangcai Yang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chenghao Ying
Ranok Therapeutics 13 Hangzhou
5 shared publications - Chunwei Xu
Institute of Cancer and Basic Medicine (ICBM) Chinese Academy of Sciences Hangzhou China
5 shared publications - Guoqiang Wang
Ranok Therapeutics 15 Hangzhou, Zhejiang
5 shared publications - Han Si
Zhejiang Cancer Hospital 4 Hangzhou
5 shared publications - Haolin Song
Zhejiang Cancer Hospital 8 Hangzhou, Zhejiang
5 shared publications - Iman Ei-Hariry
Ranok Therapeutics (Hangzhou) 14
5 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
KRASG12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRASG12D inhibitor that inhibits proliferation of KRASG12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune checkpoint blockade (ICB). In a phase Ia study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non–small cell lung cancer (NSCLC), the objective response rate (ORR; unconfirmed) was 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC), the ORR (unconfirmed) was 33.33% in the 1,000- to 1,200-mg cohort. This study supports the clinical potential of RNK08954 in patients with KRASG12D mutation either as a single agent or in combination.Significance:RNK08954 is potentially the first orally bioavailable KRASG12D inhibitor, distinguished by unique PK properties, preclinical efficacy, preliminary clinical activity with encouraging results in patients with NSCLC and PDAC, and synergistic potential with ICB. RNK08954 may address a critical unmet need by targeting the most prevalent KRAS mutation across solid tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
KRASG12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRASG12D inhibitor that inhibits proliferation of KRASG12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune checkpoint blockade (ICB). In a phase Ia study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non–small cell lung cancer (NSCLC), the objective response rate (ORR; unconfirmed) was 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC), the ORR (unconfirmed) was 33.33% in the 1,000- to 1,200-mg cohort. This study supports the clinical potential of RNK08954 in patients with KRASG12D mutation either as a single agent or in combination.Significance:RNK08954 is potentially the first orally bioavailable KRASG12D inhibitor, distinguished by unique PK properties, preclinical efficacy, preliminary clinical activity with encouraging results in patients with NSCLC and PDAC, and synergistic potential with ICB. RNK08954 may address a critical unmet need by targeting the most prevalent KRAS mutation across solid tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary_figure_S1-S7 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Supplementary Figure S1. Effect of RNK08954 on KRAS signaling pathway and cell cycle. Supplementary Figure S2. RNK08954 inhibits tumor growth in various human tumor xenograft in vivo (body weight). Supplementary Figure S3. RNK08954 inhibits tumor growth in GP2d tumor xenograft in vivo. Supplementary Figure S4. KRAS G12D inhibition reprograms the immune microenvironment. Supplementary Figure S5. KRAS G12D inhibition increased CD8+ T cell population. Supplementary Figure S6. Exposure at C1D8 of RNK08954 following multiple oral doses (GeoMean). Supplementary Figure S7. ctDNA clearance in NSCLC patients with KRAS G12D mutation treated with RNK08954 from Phase 1a dose escalation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_figure_S1-S7 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Supplementary Figure S1. Effect of RNK08954 on KRAS signaling pathway and cell cycle. Supplementary Figure S2. RNK08954 inhibits tumor growth in various human tumor xenograft in vivo (body weight). Supplementary Figure S3. RNK08954 inhibits tumor growth in GP2d tumor xenograft in vivo. Supplementary Figure S4. KRAS G12D inhibition reprograms the immune microenvironment. Supplementary Figure S5. KRAS G12D inhibition increased CD8+ T cell population. Supplementary Figure S6. Exposure at C1D8 of RNK08954 following multiple oral doses (GeoMean). Supplementary Figure S7. ctDNA clearance in NSCLC patients with KRAS G12D mutation treated with RNK08954 from Phase 1a dose escalation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary_table_S1-S3 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Supplementary Table S1 Single Intravenous or Oral Dose PK of RNK08954 in the Mice. Supplementary Table S2 Summary of Baseline Characteristics - Phase 1a of RNK08954. Supplementary Table S3 Pharmacokinetic Parameters of RNK08954 Following Multiple Oral Doses of Phase 1a
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary_table_S1-S3 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Supplementary Table S1 Single Intravenous or Oral Dose PK of RNK08954 in the Mice. Supplementary Table S2 Summary of Baseline Characteristics - Phase 1a of RNK08954. Supplementary Table S3 Pharmacokinetic Parameters of RNK08954 Following Multiple Oral Doses of Phase 1a
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials & Methods 1 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Additional information for materials and Methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials & Methods 1 from Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
Additional information for materials and Methods
- Open Access
- 21 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (5) , 895-910
Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor
KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune check blockade (ICB). In a Phase 1a study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR, unconfirmed) is 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC) the ORR (unconfirmed) was 33.33% in the 1000-1200mg cohort. This study supports the clinical potential of RNK08954 in patients with KRAS G12D mutation either as a single agent or in combination.
- 21 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (5) , 895-910
Open AccessPreclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor
KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune check blockade (ICB). In a Phase 1a study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR, unconfirmed) is 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC) the ORR (unconfirmed) was 33.33% in the 1000-1200mg cohort. This study supports the clinical potential of RNK08954 in patients with KRAS G12D mutation either as a single agent or in combination.